Fernando Rivera
Overview
Explore the profile of Fernando Rivera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
10407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rivera F, Longo F, Martin Richard M, Richart P, Alsina M, Carmona A, et al.
Clin Transl Oncol
. 2024 Jul;
26(11):2826-2840.
PMID: 39023829
Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, the incidence is lower and GC represents the tenth...
2.
Garcia-Alfonso P, Vera R, Aranda E, Elez E, Rivera F
Clin Transl Oncol
. 2024 Feb;
26(6):1429-1437.
PMID: 38411748
Purpose: The optimal drug regimen and sequence are still unknown for patients with metastatic colorectal cancer (mCRC) who are candidates for third-line (3L) or subsequent treatment. The aim of this...
3.
Carrato A, Pazo-Cid R, Macarulla T, Gallego J, Jimenez-Fonseca P, Rivera F, et al.
NEJM Evid
. 2024 Feb;
3(2):EVIDoa2300144.
PMID: 38320486
BACKGROUND: Sequential nab-paclitaxel plus gemcitabine followed by modified FOLFOX-6 (oxaliplatin, leucovorin, and 5-fluorouracil) (nab-P/Gem-mFOLFOX) showed a good safety and clinical profile in metastatic pancreatic ductal adenocarcinoma (mPDAC) in the phase...
4.
Riveiro-Barciela M, Carballal S, Diaz-Gonzalez A, Manosa M, Gallego-Plazas J, Cubiella J, et al.
Gastroenterol Hepatol
. 2024 Jan;
47(4):401-432.
PMID: 38228461
The development of the immune checkpoint inhibitors (ICI) is one of the most remarkable achievements in cancer therapy in recent years. However, their exponential use has led to an increase...
5.
Riveiro-Barciela M, Carballal S, Diaz-Gonzalez A, Manosa M, Gallgo-Plazas J, Cubiella J, et al.
Rev Esp Enferm Dig
. 2024 Jan;
116(2):83-113.
PMID: 38226597
The development of the immune checkpoint inhibitors (ICI) is one of the most remarkable achievements in cancer therapy in recent years. However, their exponential use has led to an increase...
6.
Rha S, Oh D, Yanez P, Bai Y, Ryu M, Lee J, et al.
Lancet Oncol
. 2023 Oct;
24(11):1181-1195.
PMID: 37875143
Background: PD-1 inhibitors combined with chemotherapy have shown efficacy in gastric or gastro-esophageal junction cancer. We compared the efficacy and safety of pembrolizumab plus chemotherapy with placebo plus chemotherapy in...
7.
Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al.
J Clin Oncol
. 2023 Jul;
41(21):3663-3669.
PMID: 37459755
Purpose: To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic...
8.
Armien B, Munoz C, Cedeno H, Salazar J, Salinas T, Gonzalez P, et al.
Viruses
. 2023 Jun;
15(6).
PMID: 37376694
Twenty years have passed since the emergence of hantavirus zoonosis in Panama at the beginning of this millennium. We provide an overview of epidemiological surveillance of hantavirus disease (hantavirus pulmonary...
9.
Yoshino T, Andre T, Kim T, Yong W, Shiu K, Jensen B, et al.
Cancer Sci
. 2022 Nov;
114(3):1026-1036.
PMID: 36369901
The phase 3 KEYNOTE-177 study evaluated pembrolizumab versus chemotherapy with or without bevacizumab or cetuximab in patients with newly diagnosed, microsatellite-instability-high (MSI-H)/mismatch-repair-deficient (dMMR) metastatic colorectal cancer (mCRC). Primary endpoints were...
10.
Mulet N, Valladares-Ayerbes M, Vieitez J, Gravalos C, Garcia-Alfonso P, Santos C, et al.
Eur J Cancer
. 2022 Nov;
177:154-163.
PMID: 36335783
Purpose: The purpose of this article is to evaluate the safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients. Patients And Methods: Patients with mCRC and...